AbbVie 2012 Annual Report Download - page 9

Download and view the complete annual report

Please find page 9 of the 2012 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 200

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200

anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1.
AbbVie’s 2012 sales of Kaletra totaled $1.0 billion.
Norvir. Norvir (ritonavir) is a protease inhibitor that is indicated in combination with other
antiretroviral agents for the treatment of HIV-1 infection. AbbVie’s 2012 sales of Norvir totaled
$389 million.
Endocrinology products. Lupron (also marketed as Lucrin and Lupron Depot) is a product for the
palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious
puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron
is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month
intramuscular injection. Lupron generated sales of approximately $800 million in 2012 in select markets
worldwide.
Dyslipidemia products. AbbVie’s dyslipidemia products address the range of metabolic conditions
characterized by high cholesterol and/or high triglycerides. These products, which generated sales of
$2.1 billion in 2012, are primarily marketed to primary care physicians, and include:
TriCor and TRILIPIX. TriCor and TRILIPIX are fibric acid derivatives that are indicated as
adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, which are key
contributors to cardiovascular disease, and to increase HDL cholesterol levels. AbbVie has the
rights to sell TriCor and TRILIPIX only in the United States. AbbVie’s 2012 combined sales of
TriCor and TRILIPIX totaled $1.1 billion.
Niaspan. Niaspan is an extended release form of niacin that is indicated as an adjunct to diet
to reduce total cholesterol, LDL cholesterol, and triglyceride levels, and to increase HDL
cholesterol levels. AbbVie has the rights to sell Niaspan only in the United States. AbbVie’s 2012
sales of Niaspan totaled $911 million.
Other products. AbbVie’s other products include the following:
Synagis. Synagis is a product marketed by AbbVie outside of the United States that protects
at-risk infants from severe respiratory disease, or respiratory syncytial virus (RSV). AbbVie’s 2012
sales of Synagis totaled $842 million.
Anesthesia products. Sevoflurane (sold under the trademarks Ultane and Sevorane) is an
anesthesia product that AbbVie sells worldwide for human use. AbbVie’s 2012 sales of Sevoflurane
totaled $602 million.
Duodopa and Duopa. Duodopa is a levodopa-carbidopa intestinal gel (LCIG) marketed
outside of the United States to treat advanced Parkinson’s disease. AbbVie’s 2012 sales of
Duodopa totaled $149 million. The LCIG therapy has completed Phase III development for the
United States under the name Duopa, and AbbVie is pursuing regulatory approval in 2013 in the
United States.
Zemplar. Zemplar is a product sold worldwide for the prevention and treatment of secondary
hyperparathyroidism associated with Stage 3, 4, and 5 chronic kidney disease (CKD). AbbVie’s
2012 sales of Zemplar totaled $383 million.
Research and Development Activities
AbbVie has numerous compounds in clinical development, including potential treatments for
highly prevalent conditions. Over the past five years, AbbVie has more than doubled the number of
compounds in its pipeline through a mix of internal development and external collaboration efforts.
AbbVie’s ability to discover and develop new compounds is enhanced by the company’s use of
3